Enfusion, Inc. (NYSE:ENFN) CFO Bradley Herring Sells 1,533 Shares

Enfusion, Inc. (NYSE:ENFN - Get Free Report) CFO Bradley Herring sold 1,533 shares of the company's stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $11.48, for a total value of $17,598.84. Following the completion of the sale, the chief financial officer now owns 329,334 shares in the company, valued at approximately $3,780,754.32. This represents a 0.46 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Bradley Herring also recently made the following trade(s):

• On Wednesday, March 5th, Bradley Herring sold 4,645 shares of Enfusion stock. The shares were sold at an average price of $11.38, for a total value of $52,860.10.
• On Wednesday, March 5th, Bradley Herring sold 4,645 shares of Enfusion stock. The shares were sold at an average price of $11.38, for a total value of $52,860.10.
• On Tuesday, January 7th, Bradley Herring sold 4,134 shares of Enfusion stock. The shares were sold at an average price of $10.13, for a total value of $41,877.42.
• On Friday, December 20th, Bradley Herring sold 24,443 shares of Enfusion stock. The shares were sold at an average price of $10.61, for a total value of $259,340.23.

Enfusion Stock Down 0.5 %

Shares of ENFN stock traded down $0.06 during trading hours on Friday, hitting $11.24. 970,369 shares of the company's stock were exchanged, compared to its average volume of 1,164,913. The firm has a market cap of $1.44 billion, a P/E ratio of 280.95, a P/E/G ratio of 1.85 and a beta of 0.95. The firm has a 50 day moving average of $10.98 and a two-hundred day moving average of $9.89. Enfusion, Inc. has a fifty-two week low of $7.83 and a fifty-two week high of $11.80.

Remove Ads

Enfusion (NYSE:ENFN - Get Free Report) last announced its earnings results on Monday, March 3rd. The company reported $0.01 earnings per share for the quarter, missing the consensus estimate of $0.03 by ($0.02). The business had revenue of $52.94 million for the quarter, compared to analyst estimates of $53.98 million. Enfusion had a return on equity of 6.67% and a net margin of 1.70%. On average, equities analysts forecast that Enfusion, Inc. will post 0.06 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Harbor Capital Advisors Inc. increased its position in shares of Enfusion by 12.4% during the third quarter. Harbor Capital Advisors Inc. now owns 11,887 shares of the company's stock worth $113,000 after purchasing an additional 1,315 shares in the last quarter. Belvedere Trading LLC purchased a new stake in shares of Enfusion during the third quarter worth approximately $114,000. Impax Asset Management Group plc increased its position in shares of Enfusion by 25.4% during the third quarter. Impax Asset Management Group plc now owns 676,948 shares of the company's stock worth $6,424,000 after purchasing an additional 136,948 shares in the last quarter. Versor Investments LP purchased a new stake in shares of Enfusion during the third quarter worth approximately $501,000. Finally, Royce & Associates LP increased its position in shares of Enfusion by 35.4% during the third quarter. Royce & Associates LP now owns 99,715 shares of the company's stock worth $946,000 after purchasing an additional 26,045 shares in the last quarter. 81.05% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research analysts have issued reports on the company. Stifel Nicolaus boosted their price target on Enfusion from $11.00 to $13.00 and gave the company a "buy" rating in a report on Wednesday, December 18th. William Blair reissued a "market perform" rating on shares of Enfusion in a report on Monday, January 13th. Finally, Piper Sandler boosted their price target on Enfusion from $10.00 to $11.50 and gave the company a "neutral" rating in a report on Monday, December 23rd. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of "Hold" and an average target price of $11.13.

About Enfusion

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.